Log in

NASDAQ:TGTX - TG Therapeutics Stock Price, Forecast & News

$15.78
+0.59 (+3.88 %)
(As of 02/16/2020 02:18 PM ET)
Add
Today's Range
$15.26
Now: $15.78
$16.20
50-Day Range
$10.83
MA: $13.42
$15.83
52-Week Range
$4.58
Now: $15.78
$16.20
Volume1.89 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TGTX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees105
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.


TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) released its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.33. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. View TG Therapeutics' Earnings History.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for TG Therapeutics.

What price target have analysts set for TGTX?

3 equities research analysts have issued 1-year price targets for TG Therapeutics' shares. Their forecasts range from $12.00 to $24.00. On average, they expect TG Therapeutics' share price to reach $17.67 in the next year. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for TG Therapeutics.

What is the consensus analysts' recommendation for TG Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:
  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (1/18/2020)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $17 PT. On the 1Q call, TG discussed recent pipeline progress, including the interim data for umbralisib in marginal zone lymphoma (MZL) that were presented at AACR last month and potential updates over the rest of 2019 and early 2020. After positive interim data for umbralisib in MZL, another major milestone will be discussing recent positive MZL data with the FDA. The final MZL data are to be presented toward the end of 2019 (we think potentially at the meantime, the company plans to present an update at ASCO and meet with the FDA to discuss accelerated approval." (5/13/2019)
  • 3. HC Wainwright analysts commented, "Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 35% POS for umbralisib in 40% POS for ublituximab in MS." (4/12/2019)

Has TG Therapeutics been receiving favorable news coverage?

Media coverage about TGTX stock has been trending neutral on Sunday, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TG Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for TG Therapeutics.

Are investors shorting TG Therapeutics?

TG Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 13,860,000 shares, an increase of 7.8% from the January 15th total of 12,860,000 shares. Based on an average daily volume of 2,168,800 shares, the short-interest ratio is currently 6.4 days. Approximately 16.1% of the shares of the company are sold short. View TG Therapeutics' Current Options Chain.

What other stocks do shareholders of TG Therapeutics own?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.92%), State Street Corp (3.42%), FMR LLC (1.76%), Goldman Sachs Group Inc. (1.23%), Renaissance Technologies LLC (1.18%) and Candriam Luxembourg S.C.A. (0.96%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.

Which major investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., State Street Corp, Rafferty Asset Management LLC, FMR LLC, Raymond James & Associates, New York State Common Retirement Fund, Victory Capital Management Inc. and Baldwin Brothers Inc. MA. View Insider Buying and Selling for TG Therapeutics.

Which major investors are buying TG Therapeutics stock?

TGTX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Renaissance Technologies LLC, Candriam Luxembourg S.C.A., Barclays PLC, Ikarian Capital LLC, Cubist Systematic Strategies LLC, Goldman Sachs Group Inc. and Credit Suisse AG. View Insider Buying and Selling for TG Therapeutics.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $15.78.


MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  550 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  841
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel